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The constitutive heparin (HP) mast cells (MCs) in mice
express mouse MC protease (mMCP)-5 and carboxypeptidase A
(mMC-CPA). The amino acid sequence of mMCP-5 is most sim-
ilar to that of human chymase-1, as are the nucleotide sequences
of their genes and transcripts. Using a homologous recombina-
tion approach, a C57BL/6 mouse line was created that possessed
a disrupted mMCP-5 gene. The resulting mice were fertile and
had no obvious developmental abnormality. Lack of mMCP-5
protein did not alter the granulation of the IL-3/IL-9-dependent
mMCP-2 MCs in the jejunal mucosa of Trichinella spiralis-
infected mice. In contrast, the constitutive HP MCs in the
tongues of mMCP-5-null mice were poorly granulated and
lacked mMC-CPA protein. Bone marrow-derived MCs were
readily developed from the transgenic mice using IL-3. Al-
though these MCs contained high levels of mMC-CPA mRNA,
they also lacked the latter exopeptidase. mMCP-5 protein
is therefore needed to target translated mMC-CPA to the secre-
tory granule along with HP-containing serglycin proteoglycans.
Alternately, mMCP-5 is needed to protect mMC-CPA from
autolysis in the cell’s granules. Fibronectin was identified as a
target of mMCP-5, and the exocytosis of mMCP-5 from the MCs
in the mouse’s peritoneal cavity resulted in the expression of
metalloproteinase protease-9, which has been implicated in
arthritis. In support of the latter finding, experimental arthritis
was markedly reduced in mMCP-5-null mice relative to wild-
type mice in two disease models.
Human chymase-1 (hCMA1)3 (1, 2) (GenBankTM Gene ID
1215) is an enzymatically active 30-kDa serine protease
stored in the secretory granules of the constitutive mast cells
(MCs) in most connective tissues at a concentration of 4.5
pg/cell ionically bound to heparin (HP)-containing serglycin
proteoglycans (SGPGs). Although the functions of hCMA1 in
MC-dependent inflammation and connective tissue remodel-
ing have not been determined, some of its identified targets
based on in vitro studies are angiotensin-I (3), endothelin-1 (4),
IL-1 (5), TGF-1 (6), and fibronectin (7).
hCMA1 usually is coordinately expressed at an 1:1 molar
ratio with human MC carboxypeptidase A (hMC-CPA; also
known as carboxypeptidase A3) (8). These hCMA1/hMC-
CPA/HP MCs also contain large amounts of hTryptase- in
their granules. Despite its abundance in many populations of
MCs, the hCMA1 transcript and protein are highly restricted.
In that regard, only four ESTs of the 8.7 million in GenBankTM
originated from its gene. Surprisingly, the hCMA1 gene on
human chromosome 14q11.2 gave rise to the seven genes on
mouse chromosome 14C3 that encode mouse MC protease-1
(mMCP-1), mMCP-2, mMCP-4, mMCP-5/mCma1 (9), mMCP-8,
mMCP-9, and mMCP-10. The reason why mouse MCs express
so many serine proteases in this family remains to be de-
termined, but their restricted substrate specificities probably
necessitated gene duplication to generate more proteases to
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give the mouse greater versatility and/or redundancy to carry
out varied MC-dependent biologic responses. Whatever the
explanation, the amino acid sequence of hCMA1 is much more
similar to that of mMCP-5 than any other chromosome 14C3
family member, as is the nucleotide sequences of its gene and
transcript. The safranin mouse MCs in the tongue, peritoneal
cavity, and numerous other connective tissues contain substan-
tial amounts of mMCP-5 protein (10 –12), and the storage of
this serine protease in the MC’s secretory granules is exquisitely
dependent on HP (13). The hMCs that increase in the synovium
of those with rheumatoid arthritis express hCMA1 (14). Like-
wise, the corresponding MCs in arthritic WT C57BL/6 (B6)
mice express mMCP-5 (15), thereby raising the possibility of
adverse roles in this inflammatory disease.
mMCP-5 and mMC-CPA are coordinately expressed in
numerous populations of in vivo and in vitro differentiated MCs
as occurs in hMCs for their homologs, whereas mMCP-4 and
the other chromosome 14C3 family members are not. Based on
these and other data, the Human and Mouse Genome Consor-
tiums concluded that mMCP-5 is the ortholog of hCMA1 (see
GenBankTM Gene ID 17228). In support of this conclusion, the
expression of its family members mMCP-1, mMCP-2, and
mMCP-4 in mouse MCs is dominantly regulated by a novel
post-transcriptional pathway (16) that is highly dependent on a
repetitive UGXCCCC nucleotide sequence (where X is any
nucleotide) in its 3-untranslated region.4 This cis-acting ele-
ment is not present in the 3-untranslated regions of the
mMCP-5 and hCMA1 transcripts. Not only is mMCP-5 also
expressed early in the differentiation of MCs from their com-
mitted progenitors, every examined mouse MC line expressed
this serine protease in contrast to its other family members.
Like hCMA1, mMCP-5 is translated as a 247-mer zymogen
that contains a 19-mer signal peptide, a 2-mer Gly-Glu propep-
tide, and a C-terminal 226-mer mature catalytic domain. Crys-
tallographic analysis of hCMA1 protein (17) and comparative
3D protein modeling studies of mMCP-5 (18) revealed these
MC-restricted serine proteases have substrate specificities
more restricted than that of pancreatic chymotrypsin because
of substantial conformational changes caused by the insertion
of 3 amino acids in the protease’s N-terminal domain, the dele-
tion of 7 amino acids in the C-terminal domain, and the loss of
a disulfide bond. hCMA1 and mMCP-5 also have conserved
faces on their surfaces that are positively charged at the granule
pH of 5.5. mMCP-5 and hCMA1 use these conformation-de-
pendent, positively charged domains to recognize the nega-
tively charged HP-SGPGs in the MC’s Golgi complex, thereby
ensuring the targeting and retention of only properly folded
protease in the cell’s secretory granules. Once in that acidic
intracellular compartment, pro-mMCP-5 and pro-hCMA1 are
proteolytically activated by dipeptidyl peptidase I/cathepsin
C (19). Because the HP-binding domains on the surfaces of
mMCP-5 and hCMA1 are Lys- and Arg-rich, both serine pro-
teases remain tightly bound to their HP-SGPGs when exocyto-
sed from activated MCs into the extracellular matrix.
When evaluated using low molecular weight substrates in the
absence of HP, the enzymatic specificity of naturally occurring
hCMA1 is more similar to that of insect cell-generated
mMCP-4 than insect cell-generated mMCP-5 (20). Problem-
atic in this and all other functional studies carried out so far on
recombinant mMCP-5, naturally occurring mMCP-5 is exocy-
tosed from activated MCs tightly bound to HP-SGPGs (10) like
the tryptase mMCP-6 (21). Thus, no free mMCP-5 exists in
vivo. Because HP dominantly regulates the substrate specificity
of mMCP-6 (22) and the rat homolog of mMCP-5 (23), the
substrate preference of naturally occurring mMCP-5 in its
physiologic state ionically bound to HP-SGPG has not been
deduced.Likewise,theimportanceofmMCP-5invariedMC-de-
pendent diseases remains to be determined.
We now describe the generation of a mMCP-5-null B6
mouse line that has been backcrossed extensively against WT
B6 mice to ensure that there is no other disrupted gene in the
transgenic mouse line, as well as to ensure the resulting mice
are histocompatible with WT B6 mice. We show that these
mice can be used to better understand the function of mMCP-5.
In that regard, we show mMCP-5 is essential for packaging of
mMC-CPA protein in the MC’s granule. We then show that
fibronectin is a target of naturally occurring mMCP-5 when
bound to HP-SGPG, that this serine protease regulates matrix
metalloproteinase-9 (MMP-9)/gelatinase B expression in vivo,
and that mMCP-5 has prominent adverse roles in two widely
used arthritis models.
Results
Generation of a mMCP-5-null B6 Mouse Strain and Charac-
terization of the MCs in These Transgenic Animals—Using a
homologous recombination approach and the methodology
described under “Experimental Procedures,” a mMCP-5-null
B6 mouse strain was created (Fig. 1, A and B). Because most of
the mMCP-5 ESTs in the GenBankTM database originated from
the mouse’s fetus (see UniGene Mm.1252), there was some
concern that it might not be possible to obtain an adult mMCP-
5-null mouse using a direct knock-out approach. Fortunately,
mMCP-5-null mice were born at the expected Mendelian ratio,
and these animals exhibited no obvious abnormality as they
aged. mMCP-5 is therefore not essential for the fertility or
development of the mouse when housed in a pathogen-free
animal facility.
The MCs that increase in number in the jejunal mucosa dur-
ing a Trichinella spiralis infection of WT mice preferentially
express mMCP-2, whereas the constitutive MCs that reside in
the jejunal muscle and submucosa preferentially express
mMCP-5 and mMCP-6. We therefore investigated the conse-
quences of disruption of the mMCP-5 gene on the different
populations of MCs in the jejunum following helminth infec-
tion. As occurs in WT mice (24), the number of CE/
mMCP-2 MCs markedly increased in the jejunal mucosa of
helminth-infected mMCP-5-null mice (Fig. 2, A and D).
Because the expression of mMCP-2 in this population of MCs is
highly dependent on the T-cell cytokines IL-3 (25) and IL-9
(26), the mucosal MCs in our mMCP-5-null mice do not have
defects in their IL-3 and IL-9 signaling pathways.
4 S. M. Lyons, R. L. Stevens, P. M. Hansbro, and P. Ivanov, unpublished
observation.
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In agreement with the genotyping data (Fig. 1), the constitutive
MCs in the muscle and submucosa of mMCP-5-null mice lacked
this chromosome 14C3 family member (Fig. 2C). Despite the
absence of mMCP-5 protein, these muscle/submucosal MCs con-
tained abundant amounts of mMCP-6 protein as assessed immu-
nohistochemically (Fig. 2B). Thus, disruption of the mMCP-5 gene
did not diminish the expression and granule accumulation of
mMCP-2 or mMCP-6 in the different populations of MCs that
reside in the mouse’s jejunum. Because the constitutive MCs that
reside in muscle, submucosa, and other connective tissues require
KL and its receptor Kit/CD117 (for review, see Ref. 27), Kit/KL
signaling pathways also were intact in mMCP-5-null MCs.
Although MC-committed progenitors could home to all ana-
lyzed tissues of the mMCP-5-null mouse, the constitutive MCs
in the tongue (Fig. 3) and peritoneal cavity (data not shown) of
the transgenic mice were poorly granulated when compared
with WT mice. The MCs in the tongues of WT BALB/c and B6
mice constitutively contained high levels of mMCP-5 (Fig. 3h),
mMCP-6 (Fig. 3i), and mMC-CPA (Fig. 3j) protein. In contrast,
the corresponding MCs in the transgenic BALB/c and B6
mouse lines contained no mMCP-5 protein (Fig. 3b) and almost
no mMC-CPA protein (Fig. 3e).
The passive cutaneous anaphylaxis (PCA) reaction in WT
mice is dependent on the release of histamine from the IgE/
FIGURE 1. Targeted disruption of the mMCP-5 gene in B6 mice. A, in the targeting vector, a portion of the mMCP-5 gene (including part of intron 2 and exon
3) was deleted. The Neor gene was then placed at the disrupted locus. Although the HSV-TK gene also was placed 3 of the targeting construct in case negative
selection had to be used to obtain ES cell clones with a disrupted allele of the mMCP-5 gene, only positive selection was used to obtain ES cell clones that
underwent correct homologous recombination. B, a PCR approach was devised to expedite the genotyping of mMCP-5-null mice. Depicted are representative
PCR analyses carried out on genomic DNA isolated from the tail of mMCP-5 knock-out (lane 2), heterozygous (lane 3), and WT mice (lane 4) using primers that
reside 5 and 3of exon 3 of the mMCP-5 gene. The presence of the Neor gene in the mutated mMCP-5 gene causes the generation of a larger DNA fragment.
Molecular weight markers are indicated in lane 1.
FIGURE 2. Analysis of the MCs in the jejunum of helminth-infected mice. A–D, sections of jejunum from T. spiralis-infected mMCP-5-null mice at day 14 were
evaluated cytochemically for the presence of CE MCs (A) or immunohistochemically for the presence of mMCP-6 (B), mMCP-5 (C), and mMCP-2 (D) MCs.
Arrows point to muscle/submucosa mMCP-6 MCs (B) and mucosal CE (A)/mMCP-2 (D) MCs present in mMCP-5-null mice (C).
mMCP-5 in Experimental Arthritis
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antigen-activated mMCP-5 MCs in the skin (28). Despite
poor granulation, no significant differences were observed in
the MC-mediated PCA reaction between mMCP-5-null and
WT mice (data not shown). Disruption of the mMCP-5 gene
therefore did not significantly affect histamine expression and
its IgE/antigen-dependent release in response to MC activation
in the skin. Thus, FcRI signaling pathways in mMCP-5-null
MCs also was intact.
Because MCs could be generated in vitro from mMCP-5-null
mice using IL-3 (Fig. 4A), disruption of the mMCP-5 gene did
not affect the MC-committed progenitors in the bone marrow
or their ability to respond to IL-3. These data were in agreement
with the helminth infection data (Fig. 2). Although WT and
mMCP-5-null mouse bone marrow-derived MCs (mBMMCs)
contained high levels of the mMCP-6 and mMC-CPA tran-
scripts (Fig. 4B), the latter mBMMCs lacked mMC-CPA pro-
tein (Fig. 4C). Disruption of the mMCP-5 gene did not affect the
levels of mMCP-6 protein in mBMMCs (data not shown), as
occurred in vivo in helminth-infected mice (Fig. 2B). The
absence of mMCP-5 protein is therefore selective in terms of its
effect on the accumulation of mMC-CPA in mBMMCs. WT
mMCP-5 mBMMCs do not express mMCP-1, mMCP-2,
or mMCP-4 because of a post-transcriptional pathway that
catabolizes these transcripts as fast as they are produced (16).
Targeted inactivation of mMCP-5 gene did not result in a com-
pensatory expression of its other chromosome 14C3 family
members in these mBMMCs (Fig. 4B).
The characteristic staining properties of WT MCs when
incubated with cationic dyes are due to the presence of nega-
tively charged SGPGs localized within the secretory granules of
MCs ionically bound to varied proteases (for review, see Ref.
29). mMCP-5-null mBMMCs failed to stain appreciably when
incubated with toluidine or methylene blue (Fig. 4A). To eval-
uate the effects of mMCP-5 gene disruption on the biosynthesis
of SGPGs, WT and mMCP-5-null mBMMCs were metaboli-
cally labeled with [35S]sulfate. The [35S]SGPGs were purified
and subjected to CL-4B-Sepharose gel filtration chromatogra-
phy. No significant differences were observed in the amount
and size of the synthesized SGPGs by WT and mMCP-5-null
mBMMCs (data now shown). These results indicated that
mMCP-5 protein affects MC granulation by affecting the pack-
aging and/or targeting of SGPGs to the MC’s secretory granules
rather than their biosynthesis.
When co-cultured with 3T3 fibroblasts, WT mBMMCs
markedly increase their accumulation of mMCP-5 and mMC-
CPA protein (30). In this in vitro system, mMC-CPA protein
also failed to accumulate in the co-cultured mMCP-5-null
mBMMCs (Fig. 5). These results indicated that mMCP-5 pro-
tein is needed to target translated mMC-CPA protein to the
secretory granule or to protect the later neutral protease from
autolysis. Because mMCP-5 is a major granule constituent of
IL-3-developed mBMMCs, its absence in mMCP-5-null mBM-
MCs significantly affected the serine protease activity present
in the lysates of mBMMCs before and after fibroblast co-cul-
ture, as measured by a [3H]diisopropyl fluorophosphate (DFP)
binding assay (data not shown).
We previously showed that WT mMCP-4/mMCP-5/
mMCP-6 mBMMCs release an undefined serine protease that
rapidly degrades fibronectin in vitro (31). As noted in Fig. 6, the
FIGURE 3. Histochemical and immunohistochemical evaluation of tongue MCs in WT and mMCP-5-null mice. a–j, serial sections (a– c, d–f, and g–j) of
tongue from mMCP-5-null (a–f) or WT (g–j) mice were stained with methylene blue (a, d, and g), anti-mMCP-5 antibody (b and h), anti-mMCP-6 antibody (c, f,
and i), or anti-MC-CPA antibody (e and j). The MCs in the tongue of WT mice have granules filled with HP (g), mMCP-5 (h), mMCP-6 (i), and mMC-CPA (j). As
expected, disruption of the mMCP-5 gene resulted in MCs unable to express mMCP-5. Although these MCs contained variable amounts of mMCP-6 (c and f),
they were unable to store HP (a and d) and mMC-CPA (e) in their granules.
FIGURE 4. Analysis of WT and mMCP-5-null mBMMCs. A, cytospins of
mMCP-5-null (/) and WT mBMMCs (/) were stained with toluidine
blue. B, RNA blot analyses were carried out to evaluate the levels of the tran-
scripts that encode mMCP-1, mMCP-2, mMCP-4, mMCP-5, mMCP-6, mMC-
CPA, and -actin in mMCP-5/ (data not shown), mMCP-5/, and mMCP-
5/ mBMMCs. C, lysates of these three populations of mBMMCs also were
evaluated for their mMCP-5 and mMC-CPA protein levels by SDS-PAGE/im-
munoblot analysis.
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relevant protease is mMCP-5 rather than mMCP-6 or another
chromosome 14C3 family member. Because mMC-CPA is an
exopeptidase with a limited substrate preference for C-terminal
aromatic and hydrophobic amino acids (30), the Fig. 6 data
were not a consequence of a lack of mMC-CPA protein in
mMCP-5-null mBMMCs.
In support of the Fig. 6 data, there was a noticeable difference
in the expression and/or post-translational processing of
numerous proteins in the fibroblastmBMMC co-cultures
depending on whether the latter immune cells were generated
from WT or mMCP-5-null mice (Fig. 7 and supplemental Table
S1). For example, protein 38 was selectively expressed in the
co-culture that contained WT mBMMCs. The MS fingerprint
data of six peptides in its trypsin digest revealed this protein was
mMC-CPA, thereby confirming the SDS-PAGE immunoblot
data in Fig. 5. This finding also validated the two-dimensional
difference gel electrophoresis (2D-DIGE) approach that docu-
mented the importance of mMCP-5 in the co-culture system.
The observation that three of the differentially expressed
proteins in the mBMMCfibroblast co-cultures were isoforms
of serpinB1 (supplemental Table S1) suggests that this protease
inhibitor is a naturally occurring inactivator of mMCP-5.
Mouse 3T3 fibroblasts lose their contact inhibition and
increase their cellular proliferation when co-cultured with WT
mBMMCs (32). Interestingly, some of the other differentially
expressed and/or post-translationally modified proteins in the
two co-cultures corresponded to those intracellular proteins
that participate in cellular adhesion and/or proliferation (e.g.
vimentin, scinderin, and vinculin). The latter data raise the pos-
sibility that mMCP-5 is one of the factors constitutively
released from the co-cultured WT mBMMCs that regulates
varied intracellular processes in the co-cultured fibroblasts.
mMCP-5-dependent Expression of Biologically Active Pro-
teins in the Peritoneal Cavity—The constitutive MCs in the
peritoneal cavity of WT mice degranulate when exposed in vivo
or in vitro to compound 48/80 (C48/80). This reagent was
therefore injected into the peritoneal cavities of WT and
mMCP-5-null B6 mice. 30 and 120 min post-challenge, the
peritoneal cavity fluids were harvested, and the levels of 96 bio-
logically active proteins in the samples were determined at each
time point (Fig. 8 and supplemental Table S2). Differences were
noted in the levels of eotaxin-2, MIP-1, p-selectin, Vcam-1, and
insulin-like growth factor-1. However, the most impressive
data were markedly reduced levels of MMP-9/gelatinase B in
the peritoneal cavity fluid of mMCP-5-null mice 2 h after expo-
sure to C48/80 relative to similarly treated WT mice.
Inflammatory Arthritis—Whether mice were subjected to
the K/BxN mouse serum transfer (Fig. 9) or the methylated
albumin (meBSA)/IL-1 disease models (Fig. 10), arthritis was
significantly reduced in mMCP-5-null B6 mice relative to WT
B6 mice. The clinical index (Fig. 9A), ankle thickness (Fig. 9B),
inflammation (Fig. 9C), bone erosion (Fig. 9C), cartilage
destruction (Fig. 9C), and aggrecan proteoglycan loss from the
diseased cartilage (Fig. 9D) were all significantly reduced when
mMCP-5-null B6 mice were subjected to the K/BxN arthritis
model relative to similarly treated WT B6 mice. Similar data
were obtained when the two mouse strains were subjected to
the meBSA/IL-1 arthritis model (Fig. 10, A–C).
Discussion
Of the seven mouse MC chromosome 14C3 family members,
mMCP-5 (9) is the closest homolog of hCMA1 (1) at the gene,
transcript, and protein levels. A homologous recombination
approach therefore was used to disrupt the mMCP-5 gene in B6
mice (Fig. 1) to evaluate the function of this mouse chromo-
some 14C3 family member in disease models. WT mice expe-
rience a pronounced MC hyperplasia in their intestinal mucosa
during a helminth infection that peaks at day 14 (12). These
chloroacetate esterase (CE) MCs express mMCP-2 (33), in
contrast to the constitutive mMCP-5/mMCP-6 MCs that
reside in the muscle/submucosa layer of the jejunum. Large
numbers of IL-3/IL-9-dependent CE/mMCP-2 MCs accu-
mulated in the intestinal mucosa of the helminth-infected
mMCP-5-null animals (Fig. 2). Likewise, mMCP-6 MCs were
found in the submucosa/muscle region of the jejunum of these
transgenic mice. In contrast, the constitutive HP MCs in the
FIGURE 5. mMC-CPA protein levels in mBMMCs before and after co-cul-
ture with fibroblasts. mMCP-5/ (lanes 1 and 2) and mMCP-5/ (lanes 3
and 4) were cultured in the absence (lanes 1 and 3) or presence (lanes 2 and 4)
of 3T3 fibroblasts for 2 weeks. Lysates of the resulting cell suspensions were
then evaluated for their levels of mMC-CPA protein by SDS-PAGE/immuno-
blot analysis.
FIGURE 6. Fibronectin is highly susceptible to naturally occurring
mMCP-5 but not mMCP-6. Lysates of mMCP-5-null (lanes 1–3), mMCP-6-null
(lanes 4 – 6), and WT (data not shown) B6 mBMMCs were incubated with
fibronectin (Fib.) for 30 (lanes 1 and 4), 60 (lanes 2 and 5), and 120 (lanes 3 and
6) min. The resulting digests were then subjected to SDS-PAGE. Undigested
fibronectin (lane 7) was incubated 120 min in the absence of mBMMC lysate as
a negative control.
mMCP-5 in Experimental Arthritis
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tongue (Fig. 3), skin, and other connective tissues of mMCP-5-
null mice were poorly granulated when compared with their
WT littermates. Despite these data, mMCP-5-null B6 mice
could mount a MC-dependent PCA reaction, thereby revealing
no significant defect in histamine expression and its FcRI-de-
pendent release.
As assessed by immunohistochemistry, tongue MCs in
mMCP-5-null mice contained mMCP-6 protein (Figs. 2 and 3)
but lacked mMCP-5 and mMC-CPA protein (Fig. 3). Disrup-
tion of the mMCP-5 gene therefore led to a selective loss of
mMC-CPA protein in this population of MCs. In support of
these data, Feyerabend and co-workers (34) discovered that tar-
geted inactivation of the mMC-CPA gene adversely affected the
accumulation of mMCP-5 protein in the granules of connective
tissue-type MCs.
The N-deactylase-N-sulfotransferase-2 (NDST-2) gene en-
codes an enzyme required for the biosynthesis of fully sul-
fated HP in MCs. When the NDST-2 gene was disrupted in
mice, the constitutive MCs in the resulting transgenic animals
could not store appreciable amounts of mMCP-5 and mMC-
CPA protein in their secretory granules (13). Although
NDST-2-null mBMMCs also could not store mMCP-5 and
mMC-CPA in their granules, the levels of mMCP-6 protein
in these in vitro differentiated MCs were comparable with
that in WT mBMMCs.
The histochemical, biochemical, and morphological similar-
ities of the MCs in mMCP-5- and NDST-2-null B6 mice sug-
gested a critical role for mMCP-5 in regulating the biosynthesis
and/or the packaging and targeting of SGPGs and/or mMC-
CPA in the secretory granules of constitutive MCs. Consistent
with this conclusion, in vivo differentiated MCs (Fig. 3) and in
vitro differentiated mBMMCs from mMCP-5-null mice (Fig.
4A) showed poor granulation when compared with the mBM-
MCs from their / and / littermates.
The ability of WT MCs to be stained by varied cationic dyes
is due to the presence of negatively charged SGPGs. No signif-
icant differences were observed in the SGPGs synthesized by
WT and mMCP-5-null mBMMCs employing a biochemical
approach. As assessed by RNA blot analysis, mBMMCs from
mMCP-5-null and WT mice contained high levels of the mMC-
CPA transcript (Fig. 4B). Despite these mRNA data, mMCP-
5-null mBMMCs lacked mMC-CPA protein (Fig. 4C). Co-
culture of these immature MCs on 3T3 fibroblasts also fail to
induce mMC-CPA protein accumulation in mMCP-5-null
FIGURE 7. 2D-DIGE analysis of protein expression in mBMMCfibroblast co-cultures. Mouse 3T3 fibroblasts were co-cultured with WT or mMCP-5-null
mBMMCs. The proteins in the resulting lysates of the two co-cultures were differentially labeled by Cy2 and Cy3, pooled, and subjected to 2D-DIGE. The
green-labeled proteins were only found in the co-cultures that contained WT mBMMCs, whereas the red-labeled proteins were only found in the co-cultures
that contained mMCP-5-null mBMMCs. Yellow-labeled proteins were found in both. Those differentially expressed proteins selected for MALDI-ToF MS
proteomic analysis (also see supplemental Table S1) are indicated.
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mBMMCs in contrast to mMCP-5/ and mMCP-5/
mBMMCs (Fig. 5).
mMCP-5 and mMC-CPA are coordinately expressed in
mouse MCs, as is hCMA1 and hMC-CPA in hMCs. Like pan-
creatic CPA, mMC-CPA has a 94-residue propeptide that is
predicted to cover its active site. Pancreatic CPA forms a com-
plex with chymotrypsinogen C that is dependent on its propep-
tide (35). Based on these data, it is likely that the pro-mMCP-5
and pro-mMC-CPA form a similar binary complex in the MC’s
endoplasmic reticulum. Because HP biosynthesis is completed
in the Golgi, it is presumed that the pro-mMCP-5pro-mMC-
CPA complex comes in contact with HP-SGPGs just before the
macromolecular complex is targeted to the cell’s secretory
granule. If either mMCP-5, mMC-CPA, or HP-SGPG is absent,
the 3-mer complex cannot accumulate in the cell’s granules.
This novel packaging mechanism presumably evolved to
ensure the close juxtaposition of positively charged mMCP-5
and mMC-CPA in a 1:1 molar ratio along the SGPG’s negatively
charged HP glycosaminoglycan chains as likely occurs in
hCMA1/hMC-CPA/HP-SGPG hMCs. The ability of both
proteases to remain tightly bound to HP after the macromolec-
ular complex is exocytosed from activated MCs ensures
mMCP-5 and mMC-CPA stay close to one another in the extra-
cellular matrix. The large size of the macromolecular complex
also sterically prevents the inactivation of mMCP-5 by 2-mac-
rogloblin and possibly other protease inhibitors.
mMCP-5 and mMC-CPA are major granule constituents of
in vitro IL-3-dependent mBMMCs. The absence of mMCP-5
significantly affected the endopeptidase activity in lysates of
mMCP-5-null mBMMCs, as assessed by the [3H]DFP assay.
This dramatic decrease in serine protease activity also abol-
ished fibronectin degradation by mMCP-5-null mBMMCs
lysates (Fig. 6). It was previously shown that an undefined
mMCP can degrade fibronectin in a HP-dependent manner
based on the observation that the digestion of fibronectin was
reduced in NDST-2-null MCs (36). Although it was concluded
that the relevant protease probably was mMCP-4, WT mBM-
MCs lack mMCP-4 mRNA and protein (37) (Fig. 4B) even
though these MCs contain an undefined serine protease that
rapidly degrades fibronectin (31) (Fig. 6). It is now apparent that
the relevant protease in IL-3-developed mBMMCs is mMCP-5
rather than mMCP-4. Nevertheless, we cannot rule out the pos-
FIGURE 8. Expression of biologically active proteins in the peritoneal cavities of WT and mMCP-5-null mice after MC activation. A, RayBiotech mouse G
series 1000 antibody arrays III and IV were used to evaluate the presence of 96 biologically active proteins in the peritoneal cavity exudates of WT (samples 1 and
2) and mMCP-5-null (samples 3 and 4) B6 mice 30 min (samples 1 and 3) and 120 min (samples 2 and 4) after these animals were given C48/80. B, MMP-9 levels
were selectively increased in the peritoneal cavity of WT mice 2 h after given C48/80 (also see supplemental Table S2).
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sibility that mMCP-4 and mMCP-5 have overlapping bioactiv-
ities in other populations of MCs as occurs for the MC’s
tetramer-forming tryptases, namely mMCP-6 and mMCP-7. In
that regard, the  chain of fibrinogen is susceptible to both
mMCP-6 (38) and mMCP-7 (39) in vivo, even though these
tryptases have somewhat different substrate preferences (22).
Histamine/hTryptase-/hCMA1 MCs are present in
increased numbers at the sites of cartilage erosion in the joints
of patients with rheumatoid arthritis (14), and it has been con-
cluded they comprise up to 5% of the immune cells in the dis-
eased synovial tissue (40). Histamine and hTryptase- have
been detected in the synovial fluids of patients with arthritis
(41). Despite the considerable amount of circumstantial data
implicating MCs in human arthritis, it was not possible to con-
clusively determine the adverse roles of these immune cells in
experimental arthritis when MC-deficient W/Wv, Wsh/Wsh,
Sl/Sld, mMCP-5-Cre, or CPA3Cre/ mice were used. One of the
problems using Kit/KL-defective W/Wv, Wsh/Wsh, Sl/Sld mice
in MC in vivo studies is that these animals have abnormalities in
neutrophils and other cell types. In regard to CPA3Cre/ (42)
and mMCP-5-Cre (43) mice, data interpretation is highly de-
pendent on the efficiency of Cre-mediated MC ablation in each
experimental animal.
An even greater problem using MC-deficient mice in a bio-
logic system is that these immune cells release 50 biologically
active factors, many of which have contrasting activities in vivo.
For example, activated MCs produce cytokines that promote
(e.g. IL-1 and TNF-) and inhibit (e.g. IL-4 and IL-13) arthritis.
Further complicating data interpretation from MC-deficient
mice, these immune cells express activating (e.g. FcRI, FcRI,
protease-activated receptor 2, toll-like receptor 4, and CD88)
and inhibitory (e.g. gp49B1/Lilrb4, CD200R, CD300a, CD300f,
and FcRIIB) receptors. The latter inhibitory receptors would
not have been identified had investigators relied solely on MC-
deficient mice in their studies. We therefore concluded the only
way to definitively determine whether mMCP-5 participates in
a disease model is to selectively knock out its gene using a
homologous recombination approach. Although arthritis was
reduced in mMCP-6-null B6 mice, inflammation and joint
destruction were less pronounced in HP-deficient mice (44 –
47). The latter data suggested that an unidentified HP-binding
endopeptidase released from the activated MCs in the diseased
joint contributes significantly to experimental arthritis.
MMP-9 has been implicated in arthritis (48). Because the
level of MMP-9 was reduced in the peritoneal cavities of C48/
80-treated mMCP-5-null mice (Fig. 7) and because the MCs in
the synovium express mMCP-5 (15), mMCP-5-null mice were
subjected to two widely used inflammatory arthritis models. As
noted in Figs. 9 and 10, mMCP-5 had prominent adverse roles
in both disease models.
It is likely that mMCP-5 participates in arthritis by multiple
mechanisms that are not mutually exclusive. Insulin and many
other peptide hormones are generated by a two-step proteolytic
processing event involving serine protease-dependent cleavage
of the pro-hormone followed by carboxypeptidase-dependent
maturation of the biologically active precursor hormone. The
observation that mMCP-5 and mMC-CPA are co-expressed in
mice at a 1:1 molar ratio and are exocytosed tightly bound to
HP-SGPG (as occurs for their human homologs) raises the pos-
sibility that the tertiary complex is used to create biologically
active factors that participate in arthritis and other MC-depen-
FIGURE 9. Inflammatory K/BxN arthritis in WT and mMCP-5-null mice. A–D, WT (●) (n  15) and mMCP-5-null (‚) (n  15) B6 mice were subjected to K/BxN
arthritis. Arthritis was significantly reduced in mMCP-5-null B6 mice relative to WT B6 as assessed by clinical index (A), ankle thickness (B), inflammation (C), bone
erosion (C), cartilage destruction (C), and aggrecan proteoglycan loss from the diseased cartilage (D).
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dent diseases. This could be explored in the future by evaluating
other MC-associated diseases.5
The finding that the levels of MMP-9 are increased in the
peritoneal cavities of WT mice but not mMCP-5-null mice
when these animals are given C48/80 (Fig. 8) raises the alternate
possibility that mMCP-5 and hCMA1 regulate the expression
and/or activation of certain MMPs that participate in connec-
tive tissue remodeling. In regard to this hypothesis, an unde-
fined chymase in dog mastocytoma activates pro-MMP-1 and
pro-MMP-3 (49). Moreover, mMCP-6 activates pro-MMP-3
and pro-MMP-13, which are additional MMPs implicated in
arthritis (50).
Fragments of fibronectin are often present in abundance
in the synovial fluid of those with arthritis (51), and the
fibronectinarthritis link has been well established. The
finding that fibronectin is a target of mMCP-5 (Fig. 6)
raises the additional possibility that mMCP-5 disrupts fi-
bronectinintegrin signaling events in the body. In this
regard, it is noteworthy that the tetramer-forming tryptases
mMCP-6, mMCP-7, and hTryptase- alter fibrinogen
integrin signaling events because the  chain of fibrinogen is
a target of these tryptases (38, 39).
There is no evidence that mouse or human MC-CPA partic-
ipates in arthritis, and the fibronectin data (Fig. 6) are not a
consequence of mMCP-5-dependent expression of mMC-CPA
in mBMMCs. Nevertheless, we cannot rule out the more
remote possibility that mMCP-5 participates in arthritis in vivo
in a more indirect manner by impacting the expression of
mMC-CPA or another factor in MCs.
Whatever the mechanism by which mMCP-5 participates in
arthritis, transgenic mice that lack this homolog of hCMA1
have no developmental abnormality. Moreover, loss of
mMCP-5 does not negatively impact the expansion and pheno-
type of the MCs in the animal’s jejunum. Importantly, the MCs
in our mMCP-5-null mice continue to express mMCP-6 (the
mouse homolog of hTryptase-), which is a tetramer-forming
tryptase that has beneficial roles in innate immunity, acquired
immunity, and the prevention of life-threatening fibrin-platelet
clots internally. In terms of the human relevance of our mouse
data, anti-hCMA1 therapy might be effective in the treatment
of those with arthritis without causing serious adverse side
effects as probably would occur in humans given a hTryptase-
inhibitor.
5 In preliminary studies carried out on our mMCP-5-null mice that had been
backcrossed only four times, mMCP-5 also had adverse roles in experimen-
tal ischemia-reperfusion injury (63) and epidermal burn injury (64), thereby
confirming the biologic importance of this homolog of hCMA1. The gen-
eration of the mMCP-5-null mouse line was not described in either of those
earlier studies.
FIGURE 10. Inflammatory meBSA/IL1 arthritis in WT and mMCP-5-null mice. A–C, meBSA/IL-1 arthritis were induced in 10 knees of 5 WT B6 mice and 10
knees of 5 mMCP-5-null B6 mice. A, representative histochemistry data are shown. B, cellular inflammation of the joint space, pannus size, and the extent of
cartilage and bone erosion were all significantly reduced in the diseased mMCP-5-null mice relative to the diseased WT mice. C, the mean total scores for the
respective groups were 17.8 versus 12.0 (WT versus 5-KO). *, p  0.05; **, p  0.01.
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Generation of a mMCP-5-null B6 Mouse Strain Using
a Homologous Recombination Approach—A 129/Sv mouse
genomic library was screened with a mMCP-5-specific cDNA
(9) to isolate the 3.2-kb 5-exon mMCP-5 gene and its 5 and 3
flanking sequences. A targeting construct (Fig. 1A) was created
in which the gene’s second intron and most of its third exon
were replaced by the Neomycin resistance (Neo) gene. If homo-
logous recombination takes place in the transfected ES cells, the
resulting mutated mMCP-5 gene will lack codons that encode
critical amino acids in this serine protease, including the cata-
lytic triad residue Asp110. Thus, no functional mMCP-5 protein
can be expressed even if truncated transcripts and/or proteins
are generated in the created transgenic animals.
In the targeting construct, 5.8 and 1.7 kb of genomic
sequence at the mMCP-5 locus was inserted 5 and 3 of the Neo
gene, respectively. The disrupted mMCP-5 gene was inserted
into the vector pBS-SK/HSVtk immediately upstream of the
HSV-TK (herpes simplex virus thymidine kinase) gene. J1
mouse ES cells were transfected with the targeting construct,
and the resulting cells were cultured in the presence of geneti-
cin to obtain cloned cells. Genomic DNA (20 g) was pre-
pared from the clones and incubated with the restriction
enzyme StuI (New England Biolabs, Beverly, MA). The digests
were fractionated on 1% agarose gels, the separated DNA frag-
ments were blotted onto nylon membranes, and the resulting
blots were exposed to a radiolabeled probe corresponding to
the 3 end of the mMCP-5 gene outside of the targeting con-
struct to identify those clones that possessed the disrupted
allele.
One of the obtained ES cell clones was microinjected into
mouse blastocysts, which were then implanted into pseudo-
pregnant foster mothers to generate the initial chimera. Using a
standard mating approach, mMCP-5/ mice were back-
crossed 10 times with WT B6 mice and 3 times with WT
BALB/c mice. A PCR approach was used to genotype the back-
crossed animals to create the final B6 mouse strain used in most
experiments. In this screening assay, samples of tail genomic
DNA were subjected to 30 cycles of PCR using primers (5-T-
CACTTGTCGGGATCTAC-3 and 5-GGTTAGCTTGGCT-
TTCTC-3) that flank exon 3 of the endogenous mMCP-5 gene.
Each cycle of the PCR consisted of a denaturation step at 94 °C
for 1 min, an annealing step at 51 °C for 1 min, and an extension
step of 72 °C for 2 min. Heterozygotes containing the WT and
disrupted alleles of the mMCP-5 gene yielded DNA fragments
of 1 and 1.5 kb, respectively, in this PCR-based assay (Fig. 1B).
All animal studies were approved by our Institutions’ Animal
Care and Use Committees.
Histochemistry, Enzyme Cytochemistry, and Immunohisto-
chemistry—mBMMCs were obtained by culturing isolated
bone marrow cells from mMCP-5-null B6 mice and their WT
littermates for at least 3 weeks in IL-3 enriched medium (52).
Some of the resulting mBMMCs were then co-cultured for an
additional 2 weeks with Swiss albino mouse 3T3 fibroblasts
(line CCL-92; American Type Culture Collection), as previ-
ously described (53). This was done to induce granule matura-
tion and the accumulation of mMC-CPA protein (30).
For histological examination, cytocentrifuge preparations of
mBMMCs and 1.5-m-thick glycolmethacrylate sections of tis-
sue from different organs of WT and mMCP-5-null mice were
stained with 0.5% solutions of methylene or toluidine blue in 0.6
M HCl. mMCP-5 and its other chromosome 14C3 family mem-
bers cleave the substrate naphthol AS-D chloroacetate (Sigma-
Aldrich) (12). Those MCs that contained substantial amounts
of CE activity were identified cytochemically (12). Tissue sec-
tions and cultured mBMMCs also were incubated with rabbit
anti-peptide antibodies specific for mMCP-5 (10) and other
MC-restricted granule proteases, as described in our earlier
publications. To confirm the immunohistochemical and en-
zyme cytochemical data, lysates of mBMMCs developed from
WT and mMCP-5-null B6 mice were electrophoresed in 12%
SDS-PAGE gels. The resulting protein blots were probed with
anti-mMCP-5 antibody.
DFP is an active site inhibitor of the serine proteases in the
MC’s secretory granules (31). Lysates of WT and mMCP-5-null
mBMMCs were therefore suspended in 33 l of 0.15 M NaCl, 20
mM Tris-HCl pH 7.4, buffer supplemented with 8 Ci of
[3H]DFP (4 Ci/nmol; Ci  37 Gbq; Amersham Biosciences).
The treated samples were incubated for 60 min at 37 °C. SDS-
PAGE loading buffer was added, and each sample was boiled for
5 min before the [3H]DFP-labeled proteins were subjected to
SDS-PAGE. The resulting gels were treated with EN3HANCE,
dried, and exposed to X-ray film.
RNA Analyses—Total RNA was isolated from IL-3-depen-
dent mBMMCs developed from WT and mMCP-5-null B6
mice. The RNA samples were applied to 1.2% agarose-formal-
dehyde gels. The gels were subjected to electrophoresis for 17 h,
the separated RNA were transferred to nylon membranes, and
the resulting blots were analyzed with gene-specific probes for
the transcripts that encode mMCP-1, mMCP-2, mMCP-4,
mMCP-5, mMCP-6, mMC-CPA, and -actin. The cDNA
probes used in these analyses were random primed with
[32P]dCTP using the Rediprime kit (GE Healthcare-Amersham
Biosciences). They were hybridized to the RNA blots at 65 °C
for 2 h in QuikHyb hybridization solution (Stratagene, San
Diego, CA). The blots were washed at room temperature in 2	
SSC containing 0.1% SDS and then at 60 °C in 0.2	 SSC con-
taining 0.1% SDS before exposure to BIOMAX film. RT-PCR
assays using primer sets from Qiagen were employed to con-
firm the RNA blot data.
Evaluation of the Ability of the Serine Proteases in WT and
mMCP-5-null mBMMCs to Cleave Fibronectin and Other
Fibroblast Proteins—We previously showed (31) that lysates of
mBMMCs developed from WT mice contain an undefined ser-
ine protease that rapidly degrades fibronectin in vitro, thereby
impacting fibronectinintregin signaling pathways. mMCP-5
(9) and mMCP-6 (54) are the most abundant serine proteases in
B6 mBMMCs, and fibronectin is highly susceptible to hCMA1
in vitro (55). IL-3-developed mBMMCs were chosen for inves-
tigation because they do not express mMCP-1, mMCP-2,
mMCP-4, mMCP-7, mMCP-8, mMCP-9, or mMCP-10.
Because of these data, 106 mBMMCs from mMCP-5-null,
mMCP-6-null (56), and WT B6 mice were sonicated separately
on ice in 1 ml of serum-free Hanks’ balanced salt solution to
liberate their enzymatically active proteases. Samples of the
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lysates were subjected to a fibronectin susceptibility assay (31)
in which 20 l of a 1 g/l solution of fibronectin (Sigma-
Aldrich) was incubated 30 min at 37 °C with 2, 4, and 10 l of
each mBMMC lysate. Fifteen l of each digest was then added
to an equal volume of 2	 SDS-PAGE buffer supplemented with
DTT. After the samples were boiled to denature their proteins,
they were subjected to SDS-PAGE. The substrate:enzyme ratio
was 100:1 in these in vitro experiments.
We previously showed that complex bilateral interactions
occur when WT mBMMCs are co-cultured for 2 weeks with
mouse fibroblasts (53). Relevant to the present study, the
amount of mMC-CPA protein markedly increased in the co-
cultured WT mBMMCs (30). Because these MCfibroblast
interactions are highly dependent on Kit/KL (57) and IL-33/
IL1RL1 (58) signaling pathways on the surfaces of the two cell
types, they are adherent to one another and to the extracellular
matrix-coated plastic-culture dishes. To begin to determine the
roles of mMCP-5 in these co-cultures, WT and mMCP-5-null
mBMMCs were co-cultured with mouse 3T3 fibroblasts for 2
weeks. Although the MCs were not induced to undergo exocy-
tosis in these experiments via the cell’s high affinity IgE recep-
tors, we previously showed biologically active factors were con-
stitutively transferred between the two cell types (53, 59).
After 2 weeks, the resulting co-cultures were washed exten-
sively with PBS to remove contaminating fetal calf serum pro-
teins from the culture medium. Denaturing buffer (7 M urea, 2 M
thiourea, 4% CHAPS, and 30 mM Tris-HCl, pH 8.8) containing
a protease inhibitor mixture (Sigma-Aldrich) was added. The
liberated cell- and extracellular matrix-associated proteins
were enriched by TCA precipitation. They were then subjected
to Applied Biomics’s 2D-DIGE/MALDI-ToF MS proteomic
analysis, using the company’s methodology. Briefly, the pro-
teins in the mBMMCfibroblast lysate samples were labeled
with either Cy3 or Cy2. Approximately equal amounts of the
tagged proteins in the two samples were pooled and subjected
to 2D-DIGE. After electrophoresis, the resulting gel of the sep-
arated proteins was scanned using a Typhoon image scanner at
different excitation wavelengths. The fluorescent green spots in
the scanned gel corresponded to proteins only present in the
WT mBMMCfibroblast co-culture. In contrast, the fluores-
cent red spots corresponded to proteins only present in the
mMCP-5-null mBMMCfibroblast co-culture. Fluorescent yel-
low spots correspond to proteins present in both co-cultures.
Differentially expressed proteins were picked from the 2D gel
using an Ettan Spot Picker, exhaustively digested by trypsin,
and then identified whenever possible by MALDI-ToF MS
using a peptide-mass fingerprinting approach that is based on
the predicted molecular weights of the trypsin-generated pep-
tides of every known mouse protein.
SGPG Expression in mBMMCs—WT mBMMCs increase
their biosynthesis and granule accumulation of HP-SGPGs
when co-cultured with fibroblasts (53). To evaluate the conse-
quences of disruption of the mMCP-5 gene on the expression of
SGPGs in MCs, mBMMCs from mMCP-5-null and WT B6
mice were evaluated before and after co-culture with 3T3 fibro-
blasts. The SGPGs produced by both populations of mMCP-5-
null mBMMCs were characterized, as previously described for
WT mBMMCs (53). Briefly, the starting mBMMCs and the
adherent cells in the mBMMCfibroblast co-cultures were
radiolabeled in culture medium supplemented with 50 Ci
of [35S]sodium sulfate/ml. After this step, each culture was
washed and then cultured for an additional 2 h in normal
medium. The mBMMCfibroblast co-cultures were then
exposed to a solution containing 0.25% trypsin and 1 mM EDTA
for 5 min to remove residual trypsin-susceptible, fibroblast-
derived [35S]proteoglycans (namely radiolabeled syndecans
and glypicans) in the co-culture.
After the detached fibroblasts and MCs were centrifuged, the
cell pellets were disrupted by the addition of 150 l of 1% Zwit-
tergent 3-12 (Calbiochem), followed by 1350 l of 4 M guani-
dine hydrochloride. The liberated intracellular [35S]SGPGs
were subjected to CsCl density gradient centrifugation (60).
Samples of the purified mBMMC-derived [35S]SGPGs before
and after fibroblast co-culture were incubated with chondroiti-
nase ABC or nitrous acid to evaluate their relative chondroitin
sulfate and HP contents, respectively, as previously described.
Other samples of the intracellular [35S]SGPGs produced by the
mMCP-5-null and WT mBMMCs were subjected to Sepharose
CL-4B column chromatography to evaluate their overall sizes.
mMCP-5-dependent Expression of Biologically Active Pro-
teins in the Peritoneal Cavity—C48/80 induces the release of
the MC’s preformed mediators (61), including mMCP-5. To
evaluate the consequences of the exocytosis of mMCP-5 in vivo,
C48/80 was injected into the peritoneal cavities of WT and
mMCP-5-null mice, as described by Fawcett (62). 30 or 120 min
latter, the treated mice were sacrificed, and PBS (10 ml) was
injected into the peritoneal cavity of each mouse. The resulting
peritoneal cavity exudates were subjected to RayBio mouse G
series 1000 antibody arrays to measure the levels of 96 biologi-
cally active proteins. To minimize false positives and negatives,
the level of each protein in the four samples was evaluated
twice.
Helminth Infection, PCA, and Arthritis—To evaluate the con-
sequence of disrupted mMCP-5 expression on the IL-3/IL-9-
dependent mMCP-2 population of MCs that increase in num-
ber in the jejunal mucosa of helminth-infected mice, mMCP-5-
null and WT B6 mice were each infected orally with 400 freshly
isolated, stage 3 T. spiralis larvae as previously described (12).
The MCs residing in the mucosa and submucosa/muscle areas
of the jejunum were phenotyped at the height of the mastocy-
tosis at day 14.
For IgE-dependent PCA reactions, 20 l of PBS with or with-
out 20 ng of anti-dinitrophenyl IgE (Sigma-Aldrich) was
injected into the separate ears of each mMCP-5-null and WT
mouse, as previously described for similar studies carried out
on HP-deficient transgenic B6 mice created by targeted inacti-
vation of the NDST-2 gene (13). Twenty-four h later, a 100-l
solution of 0.5% Evans blue containing 100 g of dinitrophenyl-
labeled albumin was injected into the tail vein of each animal.
The visual uptake of Evans blue into the ears was compared
30 min later.
The HP MCs in the arthritic synovium of WT mice express
mMCP-5 (46, 47). Thus, mMCP-5-null B6 mice also were sub-
jected to the K/BxN mouse serum transfer (44, 45) and meBSA/
IL-1 (47) arthritis models using the methodology described in
our earlier publications.
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